AstraZeneca
In Brief This Week: AstraZeneca, Arrowhead, Immix, Ensoma, Elixirgen, Ideaya Biosciences
News items for the week of Feb. 10, 2025.
More Precise Response Markers Needed for Enhertu Amid HER2 Biomarker Disruption, Researchers Say
Premium
By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.
AstraZeneca Optimistic About Phase III Camizestrant Data in 2025, Reports Strong Q4 Product Growth
Premium
If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.
CHMP Recommends European Approval for AstraZeneca, Daiichi Sankyo's Datroway in Breast Cancer
The committee's recommendation was based on data from the TROPION-Breast01 trial, which also supported the US approval of Datroway in January.
FDA Approves Roche Antibody Test as CDx for Enhertu in HER2-Ultralow Breast Cancer Patients
The tissue-based test is approved to identify a new classification in HER2 expression designated as HER2-ultralow.
Nov 19, 2024